Video

WATCH: A paradigm shift in the management of TED

Andrew Lee, MD, and Elizabeth Fortin, MD, discuss a paradigm shift in the treatment of thyroid eye disease with the new FDA approved medicine for managing TED.

In this week's discussion, Andrew Lee, MD, and Elizabeth Fortin, MD, disucss Teprotumumab, the first and only FDA approved medicine to treat thyroid eye disease (TED). They talk about the impact the drug can have on patients, cost considerations and how to use the treatment in the clinic.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
© 2025 MJH Life Sciences

All rights reserved.